Reports

Ideas That Generate Results

1. Analyst View

2. Research Methodology

3. Psoriasis: An Overview

4. Market Dynamics
    4.1 Drivers
          4.1.1 Rising Prevalence of Psoriasis
          4.1.2 Increasing Awareness
          4.1.3 Growing Geriatric Population
          4.1.4 Rising Healthcare Expenditure
    4.2 Challenges
          4.2.1 Patent Cliff of Blockbuster Drugs
          4.2.2 High Cost
    4.3 Opportunities
          4.3.1 Biologic Drugs Flaring Up Psoriasis Drugs Market
          4.3.2 Incessant Launch of Novel Products

5. Global Psoriasis Drugs Market Outlook 2022

6. Market Segmentation by Type of Drug Molecule
    6.1 Biologic Drugs
    6.2 Small Molecule/Chemical Drugs

7. Market Segmentation by Route of Administration
    7.1 Systemic
    7.2 Topical

8. Market Segmentation by Mechanism of Action
    8.1 TNF Inhibitors
    8.2 Interleukin Blockers
    8.3 Others

9. Market Segmentation by Geography
    9.1 North America
    9.2 Europe
    9.3 Asia-Pacific

10. Trends & Developments
      10.1 Interleukin Inhibitors Driving Psoriasis Drugs Market
      10.2 TNF-alpha Blockers for the Treatment of Psoriasis

11. Mergers, Acquisitions & Collaborations

12. Pipeline Analysis

13. Porter's Five Forces Analysis

14. Key Players
      14.1 AbbVie Inc.
      14.2 Biocon
      14.3 Pfizer Inc.
      14.4 Novartis
      14.5 Eli Lilly and Company.
      14.6 Celltrion Inc.
      14.7 Celgene Corporation
      14.8 Johnson & Johnson
      14.9 Dr.Reddy's Laboratories
      14.10 Amgen Inc.